We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PharmAkea, Celgene Collaborate
News

PharmAkea, Celgene Collaborate

PharmAkea, Celgene Collaborate
News

PharmAkea, Celgene Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PharmAkea, Celgene Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PharmAkea Inc has announced the extension of their strategic collaboration with Celgene Corporation which was established to leverage PharmAkea's proprietary drug discovery platform and novel small-molecule therapies targeting fibrotic diseases. Under the terms of the agreement, Celgene Corporation committed $9 million to PharmAkea to extend the collaboration for 9 months.

PharmAkea announced the original 3-year collaboration with Celgene in October of 2013. PharmAkea is currently conducting a Phase 1 SAD and MAD trial, as well as toxicology studies that will enable Phase 2 trials on its lead program, a small molecule LOXL2 inhibitor. The Company is also conducting IND-enabling studies in preparation for a Phase 1 trial on its second program, an Autotaxin inhibitor.

"We have been very impressed with the progress the team at PharmAkea has made over the past three years," said Rupert Vessey, President of Research and Early Development at Celgene. "This extension allows the company to further realize the potential of their programs and to complete some key activities."

"Our relationship with Celgene has been extremely collaborative," said Robert Williamson, CEO of PharmAkea. "This extension is a validation and endorsement of our work to date. We look forward to continuing our work with Celgene."

Source: Story from PharmAkea Inc. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.

Advertisement